|
213 documents found matching cs:hermans*.
|
|
of 22
Prev
Next
|
|
|
|
Showing 1-10 of 213 documents
|
1.
Harlan M. Krumholz Curriculum Vitae
|
Document Date:
|
00000000
|
|
Document Type:
|
professional qualifications
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-HER0000757-0792
|
|
Exhibit Number:
|
P365
|
|
Search Terms in Context:
|
CURRICULUM VITAE
Harlan M. Krumholz, MD, SM
Education
1980 1985 1992 1985-1986
1986-1988
1988-1989
1989-1992
BS Yale College
MD Harvard Medical School
SM Harvard School of Public Health
Internship, Internal Medicine
University of Cal
Residency, Internal Medicine
University of Cal
fornia, San Franc
fornia, San Franci
SCO
SCO
SCO
Chief Resident, Moffitt Hospital University of California, San Franci;
Cardiology Fellow, Beth Israel Hospital Harvard Medical School
Career
1992-1997
1993-2001
1995-
1996-2003
1997-2002
2002-
2003-
2004-
2005-
Assistant Professor of Medicine (Cardiology)
and Epidemiology and Public Health Yale University School of Medicine
Clinica! Coordinator, Qualidigm (Connecticut Peer Review Organization)
Director, Center for Outcomes Research and Evaluation Yale-New Haven Hospital
Co-Director, Robert Wood Johnson
Clinical Scholars Program
Yale University School of Medicine
Associate Professor of Medicine (Cardiology) and Epidemiology and Public Health Yale Un
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx14m10
|
|
| |
2.
cv study design
|
Document Date:
|
20011128
|
|
Author:
|
Reicin
|
|
Recipient:
|
Tobert
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-NJ0326037-2638
|
|
Exhibit Number:
|
P39
|
|
Search Terms in Context:
|
To:
Tobert, Jonathan A.
From:
Reicin, Alise S.
Ce
Bec:
Date:
2001-11-28 2220:42
Subject:
FW: Cv study design
Jonahan
I think you know the VIGOR results-in VIGOR there was a significant reduction in CV outcomes in patients on
naproxen versus patients on vioxx. Ed is interested in evaluating whether Naproxen is in fact a cardioprotective
agent and therefore he is suggesting studies which compare VIOXX + antiplatelet agent versus Naproxen
without an antiplatelet agent (you assume Naproxen is the anti-platelet agent) in patients who need treatment
with aspirin. Since aspirin is the standard of care and does not require steady bid dosing to be effective we think
it unlikely that physicians would want to take patiente off aspim to put them on naproxen.
We wanted to get Rory's opinion on feasability of such a study
thanks
Alise
—Original Message—
From: Demopoulos, Laura A.
Sent: Wednesday, November 21, 2001 9:43 AM
To: Reicin, Alise S.
Subject: FW: Cv study desig
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx11e10
|
|
| |
3.
MVX for Vioxx: DWA to USHH field sales force
|
Document Date:
|
20010913
|
|
Document Type:
|
memo|presentation
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-ABW0000062-0063
|
|
Exhibit Number:
|
P145
|
|
Search Terms in Context:
|
MVX for VIOXX
DWA to USHH field sales force
9/13/01
Hello everyone. This is David Anstice with a MVX going to the entire Field Sales Force. I realize you don't hear directly from me very often, but this message is one that is so important that I felt compelled to deliver it myself.
Ì understand that life on territory has been challenging lately and I'd like to talk to you about some apprehensions and concerns that I've heard. Some of you may be questioning, "Why haven't we been as strong as Pharmacia/Pfizer with physicians and consumers?" And, there's been some skepticism and questioning, "Have we been as responsive as the competition?" Let me remind you of the resources we've provided to date: A CV Letter and Press Release in May in response to the NYTimes Article, another CV letter and Press Release in August in response to the JAMA article. Additionally- in response to CV and renal issues, we've sent out a letter in response to the Whelton article, a new renal obstacle handler and overall, updated obst
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx11z10
|
|
| |
4.
Flavahan Invoices
|
Document Date:
|
20060101
|
|
Document Type:
|
invoice
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-HER0000793-0806
|
|
Exhibit Number:
|
P390
|
|
Search Terms in Context:
|
Invoice for Consulting January 2006
Nicholas A. Flavahan, PhD 1189 Circle on the Green, Columbus, OH 43235
VIOXX
Date
Hours
12/5/2005
reviewing
7
12/5/2005
reviewing
0,5
12/19/2005
reviewing
3
12/20/2005
reviewing
7.5
12/27/2005
reviewing
7.5
12/28/2005
reviewing
3
12/29/2005
reviewing
TOTAL
{hrs}
30.5
TOTAL {$)
$13,725.00
immifmmm iilllifèiiii
MM
pgNbr=1
Invoice for Consulting February 2006
Nicholas A. Flavahan, PhD 1189 Circle on the Green, Columbus, OH 43235
Vioxx
Cona/McDarby
1/2/2006
Reviewing
1/7/2006
Reviewing
1/9/2006
Reviewing
1/14/2006
Reviewing
1/15/2006
Reviewing
1/16/2006
Reviewing
1/17/2006
Reviewing
1/18/2006
Reviewing
1/19/2006
Reviewing
1/20/200S
Reviewing
1/22/2006
Reviewing
1/29/2006
Reviewing
2/2/2006
Reviewing
2/3/2006
Reviewing
2/4/2006
Reviewing
2/5/2005
Reviewing
2/6/2006
Reviewing and trip to Philadelphia
2/7/2006
Reviewing
2/B/2005
Reviewing
2/9/2006
Reviewing
2/10/2006
Revie
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx14r10
|
|
| |
5.
Avorn CV
|
Document Date:
|
20060601
|
|
Author:
|
Avorn, Jerome
|
|
Document Type:
|
professional qualifications
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-HER0000636-0700
|
|
Exhibit Number:
|
P289
|
|
Search Terms in Context:
|
Curriculum Vitae
Name:
Office Address:
Home Address:
Place of Birth:
Education:
1969 A.B. 1974 M.D.
Postdoctoral Training:
1972-74 1974-75 1974-77 1975-77
Jerome L. Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital 1620 Tremont Street, suite 3030 Boston, MA 02120
5 Circuit Road Chestnut Hill, MA 02467
New York, New York
updated: June, 2006
Columbia University, New York Harvard Medical School, Boston
Fellow in Social Studies (Medical Sociology), Harvard College
Intern in Medicine, The Cambridge Hospital, Cambridge, Massachusetts
Clinical Fellow in Medicine, Harvard Medical School
Resident in Internal Medicine, Beth Israel Hospital, Boston, Massachusetts
Licensure and Certification:
1974 1974 1977 1988
National Board of Medical Examiners
Massachusetts License Registration
Diplomate, American Board of Internal Medicine
Certification in Geriatric Medicine, American Board of Internal Medicine
Academic Appointments:
1977-79 Instructor in Pre
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx13d10
|
|
| |
6.
PI9183810
|
Document Date:
|
20020411
|
|
Document Type:
|
publication|report|brochure
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-LBL0000063-0066
|
|
Exhibit Number:
|
D273
|
|
Search Terms in Context:
|
^ MERCK & CO., INC
Whitehouse Station, NJ D8889, USA
VIOXX®
{rofecoxib tablets and oral suspension)
DESCRIPTION
VIOXX* (rofecoxib) is described fonyl)phcnyl]-3-phcnvl-2(-&W)-furaronc.
structure:
chemically as 4-[4-(nrethvlsul-It has tho following chemical
o.
\\
9183S10 VIOXX'* (rofecoxib tablets and o al suspension]
Cytochrome P45D plays a miner role in metabolism of rofecoxib. InhibiLiuii u\ CYP 3A d^LiviLy by adii iiiiüLrdLiun uT ktjL'jcuiid^ulti 400 my
daily does no: affect rofecoxib disposition. However, inducion of general
hepatic metabolic activity by administration ot the non-specitic inducer rifampin 600mg daily produces a 50% decrease in rofecoxib plasma concentrations. (Also see Drug interactions.)
Excrétion
ílüfecüxib is eliminated predominantly by hepatic metabolism with little [<\%) unchanged drug recovered ir the urine. Followirg a single radiolabeled dose of 125mgr approximately 72% of the dose was excrered into the urine as metabolites and 14% in the fe
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx16l10
|
|
| |
7.
Protocol for ibuprofen or diclofenac sodium, in an osteoarthritic elderly population
|
Document Date:
|
19970225
|
|
Document Type:
|
e-mail|report
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-AAD089564-9618
|
|
Exhibit Number:
|
D350
|
|
Search Terms in Context:
|
To: Reicin, Alise S.
From: Simon, Thomas
Cc Harper, Sean E.; Mortensen, Eric R
Bcc:
Date: 1997-02-25 22:46:11
Subject: GIOPROT1 .DOC
comments enclosed, some are stolen from eric and sean
Attachments:
GIOPROT1.DOC
MRK-AAD0089618
pgNbr=1
Product: MK-0966 Protocol/Amendment No.: (not defined) DRAFT
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK & CO., INC.
SPONSOR:
Merck & Co.. Ine
TITLE:
MK-0966 GI Clinical Outcomes Study
INVESTIGATOR(S):
PRIMARY: (not defined)
SECONDARY/SUBINVESTIGATOR: (not defined)
SITE:
INSTITUTIONAL REVIEW BOARD/ETHICAL REVIEW COMMITTEE
MK-0966 (U.S.)
IOPROTl.DOC
25FEB9720FEB97
MRK-AAD0089564
pgNbr=2
Product: MK-0966
Protocol/Amendment No.: (not defined) DRAFT
(not defined) TABLE OF CONTENTS
PAGE
PROTOCOL SYNOPSIS.................................................................................................i
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx16s10
|
|
| |
8.
The Future of Drug Safety: Promoting and Protecting the Health of the Public (IOM)
|
Document Date:
|
20060926
|
|
Document Type:
|
publication|report|advertisement
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-HER0000822-1076
|
|
Exhibit Number:
|
P469
|
|
Search Terms in Context:
|
http://www.nap.edU/catalog/11750.html
We ship printed books within 1 business day; personal PDFs are available immediately.
S&FOY
The Future of Drug Safety: Promoting and Protecting the Health of the Public
Committee on the Assessment of the US Drug Safety System, Alina Baciu, Kathleen Stratton, Sheila P. Burke, Editors
ISBN: 0-309-66600-7, 350 pages, 6x9, (2006)
This PDF is available from the National Academies Press at:
http://www.nap.edU/catalog/11750.html
Visit the National Academies Press online, the authoritative source for all books from the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the National Research Council:
• Download hundreds of free books in PDF
• Read thousands of books online for free
• Explore our innovative research tools - try the "Research Dashboard" now!
• Sign up to be notified when new books are published
• Purchase printed books and selected PDF files
Thank you for downloading this PDF. If you have c
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx15g10
|
|
| |
9.
Draft Merck text submitted with FDA changes
|
Document Date:
|
20010501
|
|
Document Type:
|
report|table|chart
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-ABW0000408-0452
|
|
Exhibit Number:
|
P8
|
|
Search Terms in Context:
|
DRAFT Merck text submitted May 2001 with FDA changes of 15 COMMENTS/SUPPORT Oct 2001 shown with revision marks (Merck changes of 16,17 ________and 18 Oct shown with revision marks in BOLD)__________________________________________
A MERCK & CO., INC.
Whitehouse Station, NJ 08889, USA
________________________________________________________________9183806
VIOXX®
(rofecoxib tablets and oral suspension)
DESCRIPTION
VIOXX* (rofecoxib) is described chemically as 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone. It has the following chemical structure:
Rofecoxib is a white to off-white to light yellow powder. It is sparingly soluble in acetone, slightly soluble in methanol and isopropyl acetate, very slightly soluble in ethano!, practically insoluble in octanol, and insoluble in water- The empirical formula for rofecoxib is C17H1404S, and the molecular weight is 314.36.
Each tablet of VIOXX for oral administration contains either 12.5 mg, 25 mg, or 50 mg of rofecoxib and the follo
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10o10
|
|
| |
10.
Presentation re: dodge ball
|
Document Date:
|
00000000
|
|
Document Type:
|
presentation
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-AAR0019773-9786
|
|
Exhibit Number:
|
P9
|
|
Search Terms in Context:
|
DODGE!
PLAINTIFF'S EXHIBIT
5
Confidential - Subject To Protective Order
MRK-AAR0019773
pgNbr=1
oxx
(rofecoxib)
it
I am concerned with the potentia edema that occurs with Vioxx."
Confidential - Subject To Protective Order
MRK-AAR00Ì9774
pgNbr=2
®
(ïofecoxib)
li
am concerned with dose-related increases in hypertension with Vioxx."
Confidential - Subject To Protective Order
MRK-AAR0019775
pgNbr=3
allÄ O °
- . .-./_y,ti^tj.r-Äi^._-.-Ä
li
Can Vioxx be used in patients using low dose aspirin?"
Confidential - Subject To Protective Order
MRK-AAR0019776
pgNbr=4
\i UiVWAIL//
I am concerned about the cardiovascular effects of Vioxx?"
Confidential - Subject To Protective Order
MRK-AARQ019777
pgNbr=5
(rofecoxib)
The competition has been in my
office telling me that the incidence
of heart attacks is greater with
Vioxx than Celebrex."
Confidential - Subject To Protective Order
MRK-AAR0019778
pgNbr=6
I fCìTarcs vi hi \ì \JIKZ\~kjMui
There is no difference between Vioxx and Celebr
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10p10
|
|
| |
|
Prev
Next
|
